R 21

Drug Profile

R 21

Alternative Names: Malaria virus-like particle vaccine - MultiMalVax; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - Multimalvax; R21

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Oxford
  • Developer GlaxoSmithKline; University of Oxford
  • Class Antimalarials; Parasitic vaccines; Subunit vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Falciparum malaria

Most Recent Events

  • 22 Apr 2017 Safety and Immunogenicity data from a phase I trial in Malaria presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (CMID-2017)
  • 01 Aug 2016 Phase-I clinical trials in Falciparum malaria (Prevention) in Burkina Faso (IM) (NCT02925403)
  • 01 Aug 2016 Phase-I/II clinical trials in Falciparum malaria (Prevention) in United Kingdom (IM) (NCT02905019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top